Syllabus: GS-III

Subject: Science & Technology

Topic: Emerging Technologies.

Context: Dr. V K Gupta was declared cancer-free after CAR-T cell therapy and paid a lower price than the international cost.

Key Provisions:

• Developed collaboratively by ImmunoACT, IIT Bombay, and Tata Memorial Hospital, the therapy, called NexCAR19, has seen success in 3 out of 15 patients.
• NexCAR19 targets B-cell cancers like leukemia and lymphoma, genetically modifying a patient’s T-cells into potent cancer fighters, and providing targeted immunotherapy.
• The therapy, is approved by